Healthcare legislation firm Frier Levitt has analyzed FDA enforcement actions towards “investigation only” peptide sellers. Their summary: the FDA considers a product’s classification dependant on its intended use, not its disclaimers. When Sites incorporate dosage guides, reconstitution instruction